• Mutation; VGNC; 54284; CCND3; Simple; p.Arg358fs (c.1071_1075delCAGAG); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; 47719; TP53; Simple; p.Ala127Val (c.380C>T); Zygosity=Heterozygous (PubMed=31175136).
  
• Mutation; VGNC; 47719; TP53; Simple; p.Arg257His (c.770G>A); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=20153049; DOI=10.1016/j.leukres.2010.01.021
Rutgen B.C., Hammer S.E., Gerner W., Christian M., de Arespacochaga A.G., Willmann M., Kleiter M., Schwendenwein I., Saalmuller A.
Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma.
Leuk. Res. 34:932-938(2010)

PubMed=22761949; DOI=10.1371/journal.pone.0040078
Rutgen B.C., Willenbrock S., Reimann-Berg N., Walter I., Fuchs-Baumgartinger A., Wagner S., Kovacic B., Essler S.E., Schwendenwein I., Nolte I., Saalmuller A., Murua Escobar H.
Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model.
PLoS ONE 7:E40078-E40078(2012)

PubMed=23365669; DOI=10.1371/journal.pone.0054464
Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D., Modiano J.F., Cvetkovic G., Tepic S.
Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation.
PLoS ONE 8:E54464-E54464(2013)

PubMed=27257868; DOI=10.1371/journal.pone.0156689
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=27639374; DOI=10.1186/s12917-016-0836-z
Roode S.C., Rotroff D.M., Richards K.L., Moore P.F., Motsinger-Reif A.A., Okamura Y., Mizuno T., Tsujimoto H., Suter S.E., Breen M.
Comprehensive genomic characterization of five canine lymphoid tumor cell lines.
BMC Vet. Res. 12:207.1-207.16(2016)

PubMed=27197945; DOI=10.1111/vco.12192
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=29674676; DOI=10.1038/s41598-018-23207-7
Taher L., Beck J., Liu W., Roolf C., Soller J.T., Rutgen B.C., Hammer S.E., Chodisetti M., Sender S., Sterenczak K.A., Fuellen G., Junghanss C., Brenig B., Nolte I., Schutz E., Murua Escobar H.
Comparative high-resolution transcriptome sequencing of lymphoma cell lines and de novo lymphomas reveals cell-line-specific pathway dysregulation.
Sci. Rep. 8:6279-6279(2018)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)

PubMed=32651429; DOI=10.1038/s41598-020-68470-9
Mizuno T., Kato Y., Kaneko M.K., Sakai Y., Shiga T., Kato M., Tsukui T., Takemoto H., Tokimasa A., Baba K., Nemoto Y., Sakai O., Igase M.
Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
Sci. Rep. 10:11476-11476(2020)